e-learning
resources
Stockholm 2007
Sunday 16.09.2007
Cellular and molecular aspects of pulmonary hypertension
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Decreased expression of the TGF-beta type I receptor ALK1 in pulmonary arterial hypertension
O. Amarie, W. Klepetko, W. Seeger, N. Weissmann, O. Eickelberg (Giessen, Germany; Vienna, Austria)
Source:
Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension
Session:
Cellular and molecular aspects of pulmonary hypertension
Session type:
Electronic Poster Discussion
Number:
482
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
O. Amarie, W. Klepetko, W. Seeger, N. Weissmann, O. Eickelberg (Giessen, Germany; Vienna, Austria). Decreased expression of the TGF-beta type I receptor ALK1 in pulmonary arterial hypertension. Eur Respir J 2007; 30: Suppl. 51, 482
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The definition of pulmonary hypertension: history, practical implications and current controversies
Should we screen for hereditary pulmonary hypertension?
Patient with ankylosing spondylitis and pulmonary hypertension
Related content which might interest you:
Imbalanced expression of the type I TGF-beta receptors ALK-1 in pulmonary fibrosis
Source: Annual Congress 2009 - Mechanisms of pulmonary inflammation and fibrosis
Year: 2009
Targeting bone morphogenic protein receptor 2 (BMPR2) signalling to treat pulmonary arterial hypertension
Source: Eur Respir J, 50 (3) 1701370; 10.1183/13993003.01370-2017
Year: 2017
Regulation of Type I cytokine receptors as a target for pulmonary arterial hypertension treatment?
Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension
Year: 2020
Macitentan modulates pulmonary mRNA levels of gremlin 1 in a rat model of pulmonary arterial hypertension
Source: International Congress 2019 – Pulmonary hypertension with lung diseases and experimental pulmonary hypertension
Year: 2019
TrkB expression is altered in hypoxia-induced pulmonary hypertension
Source: Eur Respir J 2007; 30: Suppl. 51, 606s
Year: 2007
Pharmacological activation of Nur77 enhances BMP signalling and inhibits vascular remodelling in pulmonary arterial hypertension
Source: International Congress 2018 – Pathobiology of pulmonary hypertension
Year: 2018
Targeting BMPR-II in pulmonary arterial hypertension
Source: International Congress 2016 – Pulmonary arterial hypertension: future therapeutic approaches
Year: 2016
A novel piperidine attenuates pulmonary arterial hypertension via regulating BMP2 and PTGS2 levels
Source: International Congress 2018 – Pathobiology of pulmonary hypertension
Year: 2018
NMDA receptor activation promotes vascular remodeling and pulmonary arterial hypertension
Source: International Congress 2018 – Pathobiology of pulmonary hypertension
Year: 2018
Interleukin-13-dependent regulation of endothelin-1 expression in pulmonary arterial hypertension
Source: Annual Congress 2007 - Pulmonary hypertension
Year: 2007
Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment
Source: Eur Respir J 2011; 38: 851-860
Year: 2011
NMDA receptor crosstalk with PDGFR-β and BMPR2 is involved in smooth muscle cell proliferation in pulmonary arterial hypertension
Source: International Congress 2016 – The nature of pulmonary hypertension
Year: 2016
Notch1 signalling regulates endothelial proliferation and apoptosis in pulmonary arterial hypertension
Source: Eur Respir J 2016; 48: 1137-1149
Year: 2016
Relationship between Galectin-3 and mineralocorticoid receptor in pulmonary hypertension
Source: Virtual Congress 2020 – Experimental approaches to pulmonary hypertension
Year: 2020
Mutations in the bone morphogenic protein receptor 2 promoter in heritable pulmonary arterial hypertension
Source: International Congress 2018 – Pathobiology of pulmonary hypertension
Year: 2018
IL-6 receptor overexpression in pulmonary arterial smooth muscle cells in idiopathic pulmonary hypertension
Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease
Year: 2015
Plasma receptor tyrosine kinase RET in pulmonary arterial hypertension diagnosis and differentiation
Source: ERJ Open Res, 5 (4) 00037-2019; 10.1183/23120541.00037-2019
Year: 2019
Shroom expression is attenuated in hypoxia-induced pulmonary hypertension
Source: Eur Respir J 2006; 28: Suppl. 50, 147s
Year: 2006
Overexpression of angiotensin II type 1 receptor (AGTR1) and lymphatic vasculature rarefaction is present in scleroderma with pulmonary compromised
Source: Annual Congress 2012 - Diffuse parenchymal lung disease II
Year: 2012
Endothelin-a receptor antagonists reduce eNOS gene expression in rats with chronic hypoxic pulmonary hypertension
Source: Eur Respir J 2003; 22: Suppl. 45, 271s
Year: 2003
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept